...a total of 31 HER2 positive locally advanced unresectable or metastatic gastric/gastroesophageal junction cancer (GC/GEJ) patients without prior systemic treatment were enrolled….The ORR was up to 77.8% (95% CI: 57.7, 91.4), and the DCR was 92.6% (95% CI: 75.7, 99.1)....KN026 combined with KN046 treatment had demonstrated outstanding efficacy and manageable safety in HER2 positive GC/GEJ patients without prior systemic treatment.